Keros Therapeutics, Inc. (KROS) vs Protalix BioTherapeutics, Inc. (PLX)
- Keros Therapeutics, Inc. KROS 10.66 −3.96%
- Protalix BioTherapeutics, Inc. PLX 2.62 −2.96%
Keros Therapeutics, Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Keros Therapeutics, Inc. and Protalix BioTherapeutics, Inc. are of similar size ($220.1M and $217.5M). Keros Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 10.9×. Protalix BioTherapeutics, Inc. grew revenue faster over the last twelve months: 30.1% against −84.6%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs −1,345.3%). Across the 18 metrics below, Protalix BioTherapeutics, Inc. leads on 10 and Keros Therapeutics, Inc. on 8.
Valuation
Profitability
| Metric | KROS | PLX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 69.20% | 65.16% |
| Operating margin | 0.00% | 28.89% | 0.00% |
| Net margin | 0.00% | 23.50% | 0.00% |
| Free cash flow margin | 0.00% | 9.51% | 0.00% |
| Return on equity | (17.16%) | 31.23% | (56.36%) |
| Return on assets | (15.92%) | 20.07% | (48.04%) |
| Return on invested capital | (1,345.30%) | 48.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack